Aquestive Therapeutics Other 8-K Filing
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions. The resubmission addresses a prior Complete Response Letter by including new human factors and pharmacokinetic data, notably reducing the median pouch-opening time from 17 seconds to 3 seconds. The company also filed an investor presentation from the H.C. Wainwright 28th Annual Global Investor Conference.
- Counterparty
- FDA